ORIGINAL RESEARCH

Sacubitril/valsartan Compared to Valsartan in Regressing Myocardial Fibrosis in Hypertensive Heart Disease: The REVERSE-LVH Randomized Phase 2 Trial

Brief Title: Myocardial Fibrosis and Hypertrophy Regression

Vivian Lee, MSc,[a]* Mayank Dalakoti, MD,[b]* Qishi Zheng, MBBS, MPhil, MSc[c] Desiree-Faye Toh, MSc,[a] Redha Boubertakh, PhD[a] Jennifer A Bryant, PhD[d], Tar-Choon Aw, MBBS[e], Chi-Hang Lee, MBChB, MD[b] A Mark Richards, MBChB, MD, PhD[f], Javed Butler, MD, MPH, MBA[g,h], Javier Díez, MD, PhD[I, j], Roger Foo, MD[b,k], Stuart A Cook, MBBS, PhD[a,d,l], Carolyn SP Lam, MBBS, PhD[a,d,l], Thu-Thao Le, MSc, PhD[a,m]*, Calvin WL Chin, MD, PhD[a,d,m]*

*Equal contributions as co-authors

Affiliations
[a]National Heart Research Institute of Singapore, National Heart Centre Singapore, Singapore, Singapore
[b]Department of Cardiology, National University Heart Centre Singapore, National University Health System, Singapore, Singapore
[c]Cochrane Singapore, Singapore, Singapore
[d]Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore
[e]Department of Laboratory Medicine, Changi General Hospital, Singapore, Singapore
[f]Christchurch Heart Institute, University of Otago, Christchurch, New Zealand
[g]Baylor Scott and White Research Institute, Dallas, Texas, United States
[h]Department of Medicine, University of Mississippi School of Medicine, Mississippi, United States
[i]Centre of Applied Medical Research (CIMA) and School of Medicine, University of Navarra, Pamplona, Spain
[j]Centre for Network Biomedical Research of Cardiovascular Diseases (CIBERCV), Carlos III Institute of Health, Madrid, Spain
[k]Cardiovascular Metabolic Disease Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
[l]Cardiovascular & Metabolic Disorders SRP, Duke-NUS Medical School, Singapore, Singapore
[m]Cardiovascular Academic Clinical Program (ACP), Duke-NUS Medical School, Singapore, Singapore

Address for Correspondence
Dr Calvin Chin
Department of Cardiology
5 Hospital Drive, Singapore 169609
Email: gmsccwl@nus.edu.sg
Phone: (65) 6704 8905
Fax: (65) 6844 9030

Word Count: 6365
4 Figures and 3 Tables

ABSTRACT

BACKGROUND

Diffuse interstitial fibrosis is a potential therapeutic target because of its prognostic

significance and reversibility. Sacubitril/valsartan may offer superior anti-fibrotic effects

through its dual inhibition of neprilysin and angiotensin receptors. REVERSE-LVH

compared the efficacy of sacubitril/valsartan versus valsartan in reduction of diffuse

interstitial fibrosis in patients with essential hypertension and left ventricular hypertrophy

(LVH), independent of blood pressure (BP) reduction.

METHODS

Hypertensive participants with LVH (n=78; 58±11 years) were randomized to receive

sacubitril/valsartan or valsartan for 52 weeks. Primary endpoint was an absolute reduction in

interstitial volume (extracellular volume fraction × myocardial volume) from baseline to

post-treatment, using cardiovascular magnetic resonance (CMR).

RESULTS

The mean 24h systolic BP at week 52 was similar between sacubitril/valsartan and valsartan

(125±11 and 126±11mmHg, respectively; no treatment difference between groups; P=0.379).

The absolute reduction in interstitial volume was greater with sacubitril/valsartan compared

to valsartan (**unindexed**: -5.2±5.4 versus -2.5±3.1 mL, P=0.006; **indexed to body surface**

area: -2.7±2.3 versus -1.4±1.8 mL/m^2, P=0.008). In pre-specified secondary endpoints,

sacubitril/valsartan demonstrated superior reduction in LV mass, left atrial volume and

estimated LV filling pressure compared to valsartan (P<0.02 for all). Compared to valsartan,

sacubitril/valsartan was associated with a significant reduction in NT-proBNP and high-

sensitivity cardiac troponin T concentrations.

CONCLUSIONS

Despite similar BP reduction, sacubitril/valsartan led to greater regression in diffuse

interstitial fibrosis compared to valsartan in hypertensive LVH. This was associated with

reduction in LV mass; and improvement in diastolic function and circulating cardiac markers.

These findings suggest potential for regressing diffuse interstitial fibrosis in patients with

hypertensive LVH through accessible and well-tolerated pharmacological interventions,

beyond BP control.

KEYWORDS

Diffuse interstitial fibrosis; cardiovascular magnetic resonance; hypertensive heart disease

ABBREVIATIONS

ACEI = Angiotensin-converting enzyme inhibitor

ARB = Angiotensin receptor blocker

ARNI = Angiotensin receptor-neprilysin inhibitor

BP = Blood pressure

CMR = Cardiovascular magnetic resonance

ECV = Extracellular volume

HF = Heart failure

HHD = Hypertensive heart disease

LVH = Left ventricular hypertrophy

RAAS = Renin-angiotensin-aldosterone system

INTRODUCTION

About 30% of the burden related to hypertension occurred in individuals with well-controlled

blood pressures (BP)[1]. The updated definition of heart failure (HF) stages had identified more

asymptomatic individuals in a pre-clinical stage[2]. This suggests that despite substantial

benefits associated with BP lowering, there remains opportunities to improve risk

stratification and develop therapeutic options beyond managing peripheral BP to

slow/prevent the development of symptomatic HF.

In hypertensive heat disease (HHD), left ventricular hypertrophy (LVH) occurs in response to

hemodynamic and neuro-hormonal stresses triggered by prolonged exposure to elevated BP[3].

Its pathophysiology is accompanied by an expansion in extracellular volume (ECV) due to

accumulation of extracellular matrix components and collagen deposition throughout the

myocardium. Initially reversible, diffuse interstitial fibrosis progresses to irreversible focal

replacement fibrosis because of worsening cardiomyocyte injury and death[4]. Myocardial

fibrosis significantly contributes to cardiac dysfunction, arrhythmias, and reduced coronary

perfusion, ultimately leading to HF and adverse cardiovascular outcomes[4,5]. Therefore in

addition to peripheral BP, diffuse interstitial fibrosis is a potential marker for enhancing risk

stratification and directing targeted therapies to prevent the progression of hypertensive LVH

to advanced HF stages.

Angiotensin receptor–neprilysin inhibitor (ARNI) represents a novel drug class that inhibits

the renin-angiotensin-aldosterone system (RAAS) and enhances natriuretic peptides. This

dual agent combines a neprilysin inhibitor (sacubitril) and an angiotensin receptor blocker

(ARB; valsartan). Sacubitril/valsartan has shown superior benefits over conventional ARB or

angiotensin-converting enzyme inhibitors (ACEI) monotherapy in lowering BP and

improving outcomes in those with HF and reduced LV ejection fraction (HFrEF)[6,7]. Pre-

clinical studies of mouse models have demonstrated that sacubitril/valsartan is effective in

reducing myocardial fibrosis and improving cardiac function by attenuating angiotensin II

and transforming growth factor β1 fibrotic pathways[8,9].

Using cardiovascular magnetic resonance (CMR) to quantify interstitial volume as a measure

of diffuse interstitial fibrosis non-invasively[10], the aim of the study was to compare

sacubitril/valsartan versus valsartan in reducing diffuse interstitial fibrosis in patients with

hypertensive LVH. The hypothesis was that 52 weeks of sacubitril/valsartan therapy would

result in greater regression of diffuse interstitial fibrosis compared to valsartan, independent

of BP control.

METHODS

Trial Design

The Role of ARNI in the Ventricular Remodeling in Hypertensive LVH (REVERSE-LVH)

was a prospective, randomized, open-label, blinded endpoint (PROBE) phase 2 trial

(ClinicalTrials.gov identifier: NCT03553810). The original design and methods of the trial

has been published[11]. All study procedures were conducted at the National Heart Centre

Singapore (NHCS). This was an investigator-initiated trial. All trial-related expenses,

including investigations and medications were funded by the National Medical Research

Council. Novartis did not participate in the design of the trial, analysis and interpretation of

the data.

REVERSE-LVH was reviewed and approved by the SingHealth Centralized Institutional

Review Board (CIRB ref: 2018/2182) and the Health Sciences Authority. All participants

provided written informed consent.

Trial Participants and Recruitment

Participants were recruited between June 2019 and June 2023. These participants were

screened and recruited from the REMODEL cohort, an ongoing non-interventional

prospective study to examine the role of CMR in patients with hypertension

(ClinicalTrials.gov Identifier: NCT02670031). Eligible participants were adults at least 21

years old with essential hypertension and LVH, diagnosed using Asian specific thresholds on

CMR[12].

Essential hypertension was defined as systolic BP (SBP) ≥140 mmHg and/or diastolic BP

(DBP) ≥90 mmHg at time of diagnosis, on at least one medication for BP control. Individuals

with known secondary causes of hypertension, inherited cardiomyopathies, atrial fibrillation,

and history of cardiovascular complications (such as myocardial infarction, HF and stroke)

were excluded. Other exclusion criteria included intolerance to ARBs, contraindications for

CMR, stage IV or V chronic renal disease, presence of disease with limited life expectancy

(<3 years), pregnancy and/or breast-feeding.

Randomization, Treatment and Blinding

Study participants were randomized to either sacubitril/valsartan or valsartan in a 1:1 fashion.

Randomization was performed using sealed and sequentially numbered envelopes, prepared

by the Singapore Clinical Research Institute. Crossover of treatment allocation was not

allowed, and the treatment duration was 52 weeks. Treatment allocation was not concealed

from patients. Treatment assignment and trial endpoints were concealed from the core-lab

staff analyzing the CMR images.

Sacubitril/valsartan was initiated at 50-100mg twice a day, uptitrated to maximum 200mg

twice a day; valsartan was initiated at 80-160mg once a day, uptitrated to maximum 320 mg

once a day. Medications in both treatment groups were uptitrated as tolerated to achieve a

target SBP of <140 mmHg according to contemporary guidelines at the time of study

conception[13,14]. Additional non-RAAS inhibiting anti-hypertensive agents were prescribed

where necessary. Participants who were on ACEI or ARB at the time of enrollment

underwent a washout period of two weeks before commencing trial medication to eliminate

residual RAAS-intervening effects, during which alternative medicines or uptitration of

existing concomitant anti-hypertensive agents were prescribed for BP control.

Study medications were dispensed by NHCS pharmacists after each study visit. Treatment

adherence was assessed by pill counting by the pharmacists.

Study Procedures

Baseline demographic and clinical information were obtained from participants upon

randomization. Participants were seen at the clinic with 24h ambulatory BP at weeks 4, 8, 26

and 52. Renal function tests were performed during these visits as part of safety monitoring.

Phone calls were made to the participants at weeks 12 and 38. Additional un-scheduled visits

were arranged if deemed necessary by the study team (**Supplemental Table 1**). If withdrawal

of participation occurred after 12 weeks of treatment allocation, final visit procedures

(including CMR to assess endpoints) would be performed at the time of withdrawal. At each

clinic visit, adverse events related to study treatment were assessed by the study team. If

present, they were recorded and reported to the local ethics board and the Health Sciences

Authority within the required timeline.

Cardiac volumes, function, myocardial mass, and interstitial volumes were assessed at

baseline and after 52 weeks of treatment using standardized imaging CMR protocols on the

Siemens Aera 1.5T scanner (Siemens Healthineers, Erlangen, Germany). Balanced steady-

state free precession cine images were acquired in the long-axis 2-, 3- and 4-chamber views;

and short axis cines extending from the mitral valve annulus to the apex (acquired voxel size

of $1.6 \times 1.3 \times 8.0$ mm^3 and 30 phases per cardiac cycle). T1 mapping was performed with the

Modified Look-Locker Inversion-recovery sequence, where native T1 maps were acquired

using a heartbeat scheme of 5(3)3, and post-contrast T1 maps were acquired 15 minutes after

administration of 0.1 mmol/kg gadobutrol (Gadovist; Bayer Pharma AG, Germany) using a

heartbeat scheme of 4(1)3(1)2. Details of the imaging protocol were published in the trial

protocol[11].

All CMR images were de-identified and analyzed by trained personnel at the National Heart

Research Institute Singapore CMR core-lab using CVI42 software (Circle Cardiovascular

Imaging, Calgary, Canada) according to the published analysis protocols[12,15].

Primary Trial Endpoint

The primary endpoint was the difference in absolute change in interstitial volume from

baseline to post-treatment between the two treatment groups. Interstitial volume, reflecting

diffuse interstitial fibrosis in the absence of infiltrative diseases, was derived as the product of

ECV fraction $\times$ myocardial volume. This approach of quantifying interstitial volume was

previously validated against histological fibrosis[10] and demonstrated prognostic value in

patients with HHD[16].

ECV fraction was measured using the T1 mapping module in CVI42. Hematocrit for

calculating ECV fraction was taken on the day of CMR. Myocardial volume (mL) was

calculated as myocardial mass (g) divided by the specific density of the myocardium (1.05

g/mL).

Secondary Trial Endpoints

Secondary endpoints were absolute change in CMR markers of cardiac remodeling that

included LV morphology, function (including multi-directional LV strain) and mechanics.

LV concentricity was defined by the ratio between LV mass and end-diastolic volume

(EDV). Myocyte volume was derived as the product of (1-ECV fraction) × myocardial

volume. Maximal left atrial volume was estimated based on the biplane area-length method

using the 2- and 4-chamber views, at end atrial diastole[12].

Several CMR measures of myocardial mechanics were assessed. The Remodeling Index (RI)

was used as a marker of LV wall stress[15,17]. The RI was calculated as $\frac{\sqrt[3]{EDV}}{t}$, where t is the

maximal wall thickness (cm) across the 16 myocardial segments. The ventricular-arterial

coupling ratio (VCR) was used to describe the relationship between LV and arterial system. It

was calculated as the ratio of LV end-systolic volume to stroke volume[18]. LV filling

pressures were estimated using a CMR model consisting of left atrial (LA) volume and LV

mass, which had been validated with invasively measured pulmonary wedge pressure and

demonstrated to have prognostic implications[19].

Blood samples were collected on the first and final study visit; and stored at $-80°C$.

Biochemical analyses were conducted in a single freeze-thaw cycle across two assay runs at a

College of American Pathologists-accredited laboratory (Changi General Hospital,

Singapore). Serum NT-proBNP (N-terminal pro-B-type natriuretic peptide; proBNP II STAT,

Roche Diagnostics, Germany) and hsTnT (high-sensitivity cardiac troponin T; Trop T hs

STAT; Roche Diagnostics, Germany) were measured using electrochemiluminescence

immunoassay on the Cobas E801 analyzer (Roche Diagnostics Asia Pacific, Singapore). The

lab-reported lower detection limits for NT-proBNP and hsTnT were 11 pg/mL and 3 pg/mL,

respectively. All biochemical concentrations below detection thresholds were assigned a

value of half the detection limit.

Sample Size Estimation

An estimated sample size of 70 (35 per treatment group) would provide effective power of

80% at a 5% significance level (two-sided) to detect superiority of sacubitril/valsartan over

valsartan for the primary endpoint, assuming an absolute minimum difference of 3.5 mL/m^2

in mean interstitial volume change between the two groups, a standard deviation (SD) of

5.8mL/m^2 (data subsequently published[17]) and a moderate correlation of 0.60 between

interstitial volume at baseline and week 52. This effect size was based on an estimate of the

magnitude of myocardial fibrosis regression that could be expected to translate into improved

cardiac function and clinical outcomes[8]. The study plan was to recruit 80 participants,

allowing a withdrawal rate of up to 15%.

Statistical Analysis

The endpoint comparison was based on intention-to-treat analysis, i.e., all participants were

analyzed as part of the group to which they had been randomized. Continuous variables were

presented as mean ± SD and categorical variables were expressed as count (percentage).

Skewed data were presented as medians and inter-quartile range. Comparisons between

treatment groups were performed using independent samples t-tests for continuous variables

and χ^2 test for dichotomous variables.

For primary endpoint, analysis-of-covariance (ANCOVA) was performed to adjust for

baseline covariates. Treatment group at randomization was included as fixed effect. Baseline

interstitial volume and 24h SBP were included as covariates. Results were reported as

adjusted mean difference with 95% confidence intervals (CI). Post-hoc subgroup analyses of

the primary endpoint were performed using two-way analysis of variance (ANOVA) to test

heterogeneity of treatment effects in the following subgroups: age, sex, body mass index,

whether washout was performed, LV ejection fraction, interstitial volume and 24h SBP.

Continuous covariates were categorized by median values. The hypothesis testing on

secondary endpoints was considered exploratory. The analyses were presented with effect

estimates and unadjusted 95% CI. Adjustment for multiple comparisons was not performed.

The change in NT-proBNP and hsTnT were reported as the ratio of geometric mean values at

baseline and 52 weeks. For treatment comparisons, the effective treatment ratio (ETR) was

calculated as the ratio of geometric mean changes in biomarkers between the two groups.

Statistical significance was set at P value <0.05. All analyses were performed with SPSS,

version 24 (SPSS; IBM, INC, Armonk, NY) and R, version 4.3.3 (R foundation for statistical

computing, Vienna, Austria). Graphs were created using GraphPad Prism 8.1.2 (GraphPad

Software, Inc, San Diego, CA). Statistical analyses were performed by team members who

were not involved in image analysis and participants' follow up.

RESULTS

Study Participants

A total of 80 patients were recruited, and 78 individuals were successfully randomized to sacubitril/valsartan (n=39) and valsartan (n=39) (**Figure 1**). The mean age at baseline was 58±11 years, and 32 (41%) were males. The baseline 24h mean SBP and DBP were 137±14 and 81±11 mmHg, respectively. The baseline clinical, renal function and CMR characteristics were well-balanced between the two treatment groups (**Table 1**).

The median dose prescribed in the sacubitril/valsartan group was 200 [100, 200] mg twice a day and 160 [160, 320] mg once a day in the valsartan group, respectively. A total of 50 participants required additional anti-hypertensive medications (sacubitril/valsartan group, n=26 and valsartan group, n=24; P=0.571; **Supplemental Table 2**). The overall treatment adherence rate achieved in the trial was 97% (sacubitril/valsartan group, 97%; valsartan group, 96%).

Primary Trial Endpoint

The baseline interstitial volume in the sacubitril/valsartan group was 29.2±12.8 compared to 28.0±11.3 mL in the valsartan group. After 52 weeks, sacubitril/valsartan resulted in greater regression in diffuse interstitial fibrosis compared to valsartan alone (-5.2±5.4 versus -2.5±3.1 mL, P=0.006), with an absolute between-group difference of -2.8 (95% CI: -4.8 to -0.8) mL. Similar findings were observed when interstitial volume was indexed to body surface area (-2.7±2.3 versus -1.4±1.8 mL/m^2, P=0.008), with an absolute between-group difference of -1.3 (95% CI: -2.3 to -0.4) mL/m^2. Sacubitril/valsartan resulted in an 18% reduction in interstitial volume from baseline, compared to an 8.9% reduction with valsartan.

The reduction in diffuse interstitial fibrosis remained greater in the sacubitril/valsartan group

compared to valsartan alone after accounting for baseline interstitial volume and baseline 24h

SBP (**Figure 2**).

Exploratory subgroup analysis suggested treatment heterogeneity in favor of

sacubitril/valsartan in individuals with 24h median SBP >135 mmHg, with an absolute

between-group difference of -5.2 (95% CI: -8.0 to -2.5) mL/m^2 compared to -0.5 (95% CI: -

3.2 to 2.2) mL/m^2 in those with 24h SBP ≤ 135 mmHg (P=0.016 for interaction). There was

no significant treatment heterogeneity in the other subgroups stratified by age, sex, LV

ejection fraction, baseline interstitial volume and body mass index (**Supplemental Table 3**).

Secondary Trial Endpoints

Compared to valsartan alone, sacubitril/valsartan resulted in greater reduction in indexed LV

mass (-11.2±10.3 versus -6.3±5.2 g/m^2, P=0.010) and indexed myocyte volume (-8.4±7.9

versus -4.6±4.2 mL/m^2, P=0.010). Sacubitril/valsartan also led to a greater decrease in

indexed LA volume (-9.8±8.7 versus -5.0±8.0 mL/m^2, P=0.013) and LV filling pressures (-

1.8±1.5 versus -0.9±1.1 mmHg, P=0.003) compared to valsartan, suggestive of improved

diastolic function.

There were no significant differences in changes in cardiac volumes, systolic function, and

other measures of myocardial mechanics between the treatment groups. Although

sacubitril/valsartan was associated with a statistically significant improvement in global

longitudinal strain (GLS) compared to valsartan (-0.9±2.3 versus 0.2±1.9, P=0.027), the

effect size was small and the isolated improvement in GLS was not associated with

improvement in the other strain components (**Table 2**). Similar findings were observed when

relevant CMR metrics were indexed to body surface area (**Supplemental Table 4**).

Compared to valsartan, sacubitril/valsartan was associated with a significant reduction from

baseline to 52 weeks in NT-proBNP (ETR=0.72; 95% CI: 0.54–0.91; P=0.006) and hsTnT

(ETR=0.83; 95% CI: 0.69–0.99; P=0.005).

Treatment Effects on Blood Pressure Control

Participants in both groups achieved similarly lowered 24h mean BP at all timepoints

assessed in the trial (**Figure 3**). At the end of 52 weeks, the 24h mean SBP was 125±11

mmHg with sacubitril/valsartan versus 126±11 mmHg with valsartan (P=0.762 for

comparison). This corresponded to a decrease of 13.3±13.1 and 10.6±13.4 mmHg from

baseline in the sacubitril/valsartan and valsartan groups, respectively. Treatment difference

between the two groups was not significant (-2.7 [95% CI: -8.7 to 3.3] mmHg, P=0.379).

Similarly, the 24h mean DBP at the end of study was 75±9 mmHg with sacubitril/valsartan

versus 75±12 mmHg with valsartan (P=0.943 for comparison), corresponding to a decrease

of 7.1±7.1 and 5.6±9.6 mmHg from baseline in the two respective treatment groups. The

treatment difference in 24h DBP reduction between the two groups was also not significant (-

1.5 [95% CI: -5.4 to 2.3] mmHg, P=0.426).

Adverse Events

Treatment with sacubitril/valsartan and valsartan were very well-tolerated in this trial. One

patient developed nocturnal cough with sacubitril/valsartan three months after randomization.

Symptoms improved upon dose reduction, and the participant continued with the trial. Renal

function remained stable throughout the trial (**Table 3**). There were no major adverse

cardiovascular events such as hospitalizations for HF, myocardial infarction, strokes and

deaths reported during the trial.

DISCUSSION

The main finding of REVERSE-LVH was that sacubitril/valsartan resulted in superior

reduction in diffuse interstitial fibrosis in hypertensive patients with LVH following 52

weeks of treatment compared to valsartan alone. This was accompanied by a greater decrease

in LV mass and improvement in diastolic function. There was no significant difference in

systolic function improvement between the two treatment groups (**Figure 4**).

Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis

The use of CMR in REVERSE-LVH has allowed reliable quantification of fibrosis without

invasive endomyocardial biopsies, a procedure that was required in previous studies on anti-

fibrotic therapies[20–23]. Novel CMR mapping techniques have dramatically advanced tissue

characterization non-invasively, allowing us to investigate novel anti-fibrotic therapies in

diverse populations.

ECV fraction represents the ratio of interstitium to the total myocardial volume. Although it

is widely used to measure diffuse interstitial fibrosis, its utility may be limited where

treatments affect both myocyte and interstitial compartments. In such cases, therapies that

reduce both compartments may lead to an unchanged or even increased ECV fraction. For

instance, in REVERSE-LVH, despite reductions in interstitial and myocyte volumes, both

treatment groups showed a slight increase in ECV fraction, likely due to a greater reduction

in myocyte volume relative to interstitial volume. Instead, deeper mechanistic insights can be

accomplished by separately assessing the interstitial and myocyte compartments, particularly

for novel treatments or interventions with potential effects on both compartments.

Anti-Hypertensive Therapies to Target Myocardial Fibrosis

Myocardial fibrosis is a hallmark of HF, and not all BP medications have anti-fibrotic

properties. Among conventional anti-hypertensive therapies, ACEIs or ARBs that target the

RAAS have shown the most promise in regressing biopsy-confirmed myocardial fibrosis in

HHD, independent of BP lowering effects[20,21,24]. Similarly, mineralocorticoid receptor

antagonists (MRAs) like spironolactone and eplerenone reduce serum markers of collagen

turnover and improve diastolic function on echocardiography[25–27].

Sacubitril/valsartan, a first-in-class ARNI used primarily for HFrEF, is also an effective anti-

hypertensive medication[28]. While sacubitril/valsartan is approved for hypertension in some

countries[29], its effectiveness in regressing myocardial fibrosis in patients with hypertension

has not been established. Through the REVERSE-LVH trial using CMR to assess interstitial

volume, sacubitril/valsartan demonstrated a two-fold greater reduction in diffuse interstitial

fibrosis compared to valsartan alone. Both treatment groups achieved similar BP throughout

the trial, an important feature to isolate the anti-fibrotic effects of sacubitril/valsartan from

any potential influence of BP control. It is also noteworthy that the other classes of anti-

hypertensive medications prescribed were similar between the two treatment groups.

Sacubitril/valsartan also led to greater LV mass regression compared to valsartan alone,

findings that align with results from a previous trial comparing sacubitril/valsartan and

olmesartan[30]. Overall, these results reinforced the beneficial impact of sacubitril/valsartan on

reverse remodeling in patients with HHD.

REVERSE-LVH in the Context of HFpEF Trials

PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction) reported that sacubitril/valsartan did not result in significantly lower rates of HF hospitalizations and cardiovascular deaths in patients with HF and preserved ejection fraction (HFpEF) compared to valsartan[31]. Considering these results, it is important to discuss the relevance of REVERSE-LVH after PARAGON-HF and possible implications for future HFpEF trials.

HFpEF represents a syndrome characterized by phenotypic heterogeneity, underpinned by complex underlying mechanisms, and contributed by various coexisting comorbidities. This heterogeneity is exemplified by the observation that despite similar E/e' (echocardiographic marker of LV filling pressure), the prevalence of LVH ranges between 14 and 50% in recent HFpEF trials (21% in PARAGON-HF)[32]. This observation hints at the presence of additional factors contributing to elevated LV filling pressure (such as chronic lung disease, atrial fibrillation and/or chronic kidney disease). Consequently, it is plausible that not all these patients had derived the anticipated benefits from the HF medications being investigated.

To enhance the effectiveness of future HFpEF trials, one key consideration lies in the strategic inclusion of patients with common phenotypes driving the underlying pathophysiology. This approach will enable more precise selection of pharmaceutical therapies tailored at specific mechanistic phenotypes[33,34]. For instance, pirfenidone, a small-molecule anti-fibrotic agent without hemodynamic effects, reduced myocardial fibrosis in patients with HFpEF[35]. This reduction in interstitial space without significance changes in myocyte compartment explains for the overall decrease in ECV fraction. In contrast,

sacubitril/valsartan reduces both myocardial fibrosis and hypertrophy because of its effects

on hemodynamics, natriuretic and RAAS system.

Clinical Implications of REVERSE-LVH

The effectiveness of hypertension treatment is often assessed by the BP targets achieved,

with the fundamental goal to minimize end-organ complications such as HF. However,

cardiac remodeling in the hypertensive heart is complex and the peripheral BP may not

adequately reflect the abnormalities in the myocardium. A moderate correlation was

demonstrated between interstitial volume and 24h SBP (r=0.36, P<0.001), worse with office

SBP (r=0.21; P<0.01)[15]. In an unpublished analysis of REMODEL, about 54% of 224

hypertensive participants with LVH had 24h SPB <140mmHg. This poses a challenge in

defining the optimal BP targets in hypertensive patients with LVH, particularly if BP are

adequately controlled.

Because the apparent amelioration of diffuse interstitial fibrosis is associated with improved

outcomes, the interstitium is an attractive target for drug repurposing and development[4,36,37].

Sacubitril/valsartan demonstrated superior efficacy than valsartan alone in decreasing diffuse

interstitial fibrosis after 52 weeks of treatment. The observed association with improved

diastolic function was encouraging and may suggest that a longer treatment duration was

needed to reverse a long-standing process before an improvement in systolic function

becomes evident.

The findings from REVERSE-LVH strengthened the case for considering sacubitril/valsartan

in selected individuals with hypertensive LVH, especially those who failed to achieve

adequate reduction in diffuse interstitial fibrosis with ACEIs or ARBs. Individuals with 24h

SBP greater than 135mmHg (median SBP in this study) may have further reduction in diffuse

interstitial fibrosis with sacubitril/valsartan but this finding from the post-hoc subgroup

analysis was exploratory and should be investigated in future trials.

Study Strengths and Limitations

It was by chance that a higher proportion of female participants (59%) were recruited.

Despite the challenges posed by COVID-19 between 2020 and 2021, the trial had very low

dropout rates (5%) and exceptionally high treatment adherence rates, surpassing the 80%

threshold widely used to define "good adherence"[38]. Both treatment arms achieved similar

BP reduction at the end of the trial. These observations highlighted the meticulous conduct of

the trial.

The study had some limitations. Due to the relatively modest sample size, numerous variables

could not be incorporated into statistical adjustment. As baseline comparability between the

two treatment groups was achieved through randomization, statistical adjustment was

intended to further enhance the reliability of the findings. Two participants (one in each

treatment group) were given MRAs, which may confound regression of diffuse interstitial

fibrosis. This was inevitable because their BPs were not optimally controlled despite being

prescribed the maximum tolerated doses of trial medications and other classes of anti-

hypertensives. Natriuretic peptides and circulating markers of fibrosis and collagen turnover

have not been included in this study. However, they will be analyzed and reported in

subsequent studies. REVERSE-LVH was adequately powered as a phase 2 trial. However,

the relatively small sample size was insufficient to assess the effects on clinical endpoints in

patients with hypertensive LVH. Future trials with larger cohorts are needed to evaluate the

impact of diffuse fibrosis regression on clinical outcomes.

Conclusion

In patients with hypertensive LVH, sacubitril/valsartan demonstrated superior efficacy in

reducing diffuse interstitial fibrosis compared to valsartan, independent of BP control. This

was accompanied by a decrease in LV mass and improvement in diastolic function. These

findings suggested an important potential for regressing diffuse interstitial fibrosis in patients

with hypertensive LVH through accessible and well-tolerated pharmacological interventions,

beyond BP control.

Acknowledgements

506 The authors wish to thank all the study participants, the radiographers at the Department of

507 Cardiovascular Magnetic Resonance, the pharmacists at the Department of Pharmacy and the

508 research coordinators at the Clinical Trial Research Office, National Heart Centre Singapore

509 for their assistance in the study.

Disclosures

512 Prof. Lam has received consulting fees from Novartis. Prof. Butler is a consultant to

513 Novartis. The other authors do not have any relevant conflicts of interest to disclose.

Funding

REVERSE-LVH is funded by the National Medical Research Council of Singapore (MOH-

CTGIIT17may-0001).

REFERENCES

1. Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left
ventricular systolic dysfunction. *Circulation*. 2006;113(24):2851-2860.

2. Mohebi R, Wang D, Lau ES, et al. Effect of 2022 ACC/AHA/HFSA criteria on stages of
heart failure in a pooled community cohort. *J Am Coll Cardiol*. 2023;81(23):2231-2242.

3. Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure:
contemporary update. *JACC Heart Fail*. 2017;5(8):543-551.

4. González A, López B, Ravassa S, et al. Myocardial Interstitial fibrosis in hypertensive
heart disease: from mechanisms to clinical management. *Hypertens Dallas Tex 1979*.
2024;81(2):218-228.

5. González A, Schelbert EB, Díez J, Butler J. Myocardial interstitial fibrosis in heart
failure. *J Am Coll Cardiol*. 2018;71(15):1696-1706.

6. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure
reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and
neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.
Lancet Lond Engl. 2010;375(9722):1255-1266.

7. McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus
enalapril in heart failure. *N Engl J Med*. 2014;371(11):993-1004.

8. Suematsu Y, Miura S, Goto M, et al. LCZ696, an angiotensin receptor-neprilysin
inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with
reduced ejection fraction in streptozotocin-induced diabetic mice. *Eur J Heart Fail*.
2016;18(4):386-393.

9. Burke RM, Lighthouse JK, Mickelsen DM, Small EM. Sacubitril/Valsartan decreases

cardiac fibrosis in left ventricle pressure overload by restoring pkg signaling in cardiac

fibroblasts. *Circ Heart Fail*. 2019;12(4):e005565.

10. Chin CWL, Everett RJ, Kwiecinski J, et al. Myocardial fibrosis and cardiac

decompensation in aortic stenosis. *JACC Cardiovasc Imaging*. 2017;10(11):1320-1333.

11. Lee V, Zheng Q, Toh DF, et al. Sacubitril/valsartan versus valsartan in regressing

myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded

endpoint clinical trial protocol. *Front Cardiovasc Med*. 2023;10:1248468.

12. Le TT, Tan RS, De Deyn M, et al. Cardiovascular magnetic resonance reference ranges

for the heart and aorta in Chinese at 3T. *J Cardiovasc Magn Reson*. 2016;18(1):21.

13. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the

management of hypertension in the community: a statement by the American Society of

Hypertension and the International Society of Hypertension. *J Clin Hypertens*.

2014;16(1):14-26.

14. Ministry of Health, Singapore. *MOH clinical practice guidelines on hypertension 1/2017*.

Ministry   of   Health,   Singapore;   2017.

https://www.moh.gov.sg/docs/librariesprovider4/guidelines/cpg_hypertension-booklet---

nov-2017.pdf

15. Goh VJ, Le TT, Bryant J, et al. Novel Index of maladaptive myocardial remodeling in

hypertension. *Circ Cardiovasc Imaging*. 2017;10(9):e006840.

16. Iyer NR, Le TT, Kui MSL, et al. Markers of focal and diffuse nonischemic myocardial

fibrosis are associated with adverse cardiac remodeling and prognosis in patients with

hypertension: the REMODEL study. *Hypertens Dallas Tex 1979*. 2022;79(8):1804-1813.

17. Le TT, Lim V, Ibrahim R, et al. The remodelling index risk stratifies patients with

hypertensive left ventricular hypertrophy. *Eur Heart J - Cardiovasc Imaging*.

2021;22(6):670-679.

18. Holm H, Magnusson M, Jujić A, Bozec E, Girerd N. How to calculate ventricular–arterial

coupling? *Eur J Heart Fail*. 2022;24(4):600-602.

19. Garg P, Gosling R, Swoboda P, et al. Cardiac magnetic resonance identifies raised left

ventricular filling pressure: prognostic implications. *Eur Heart J*. 2022;43(26):2511-

2522.

20. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in

patients with hypertensive heart disease. *Circulation*. 2000;102(12):1388-1393.

21. Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago JL. Losartan-

dependent regression of myocardial fibrosis is associated with reduction of left

ventricular chamber stiffness in hypertensive patients. *Circulation*. 2002;105(21):2512-

2517.

22. López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effects of loop

diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. *J

Am Coll Cardiol*. 2004;43(11):2028-2035.

23. Izawa H, Murohara T, Nagata K, et al. Mineralocorticoid receptor antagonism

ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly

symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. *Circulation*.

2005;112(19):2940-2945.

24. López B, Querejeta R, Varo N, et al. Usefulness of serum carboxy-terminal propeptide of

procollagen type I in assessment of the cardioreparative ability of antihypertensive

treatment in hypertensive patients. *Circulation*. 2001;104(3):286-291.

25. Mak GJ, Ledwidge MT, Watson CJ, et al. Natural history of markers of collagen turnover

in patients with early diastolic dysfunction and impact of eplerenone. *J Am Coll Cardiol*.

2009;54(18):1674-1682.

26. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-

Sullivan T, Marwick TH. A randomized study of the beneficial effects of aldosterone

antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.

JACC Cardiovasc Imaging. 2011;4(12):1239-1249.

27. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, Marwick TH.

Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone

blockade. *Heart*. 2013;99(5):320-326.

28. Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K. Role of neprilysin inhibitor

combinations in hypertension: insights from hypertension and heart failure trials. *Eur*

Heart J. 2015;36(30):1967-1973.

29. Loo G, Puar T, Foo R, et al. Unique characteristics of Asians with hypertension: what is

known and what can be done? *J Hypertens*. 2024;42(9):1482-1489.

30. Schmieder RE, Wagner F, Mayr M, et al. The effect of sacubitril/valsartan compared to

olmesartan on cardiovascular remodelling in subjects with essential hypertension: the

results of a randomized, double-blind, active-controlled study. *Eur Heart J*.

2017;38(44):3308-3317.

31. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin–neprilysin inhibition in heart

failure with preserved ejection fraction. *N Engl J Med*. 2019;381(17):1609-1620.

32. Shah AM, Cikes M, Prasad N, et al. Echocardiographic features of patients with

heart failure and preserved left ventricular ejection fraction. *J Am Coll Cardiol*.

2019;74(23):2858-2873.

33. Palazzuoli A, Caravita S, Paolillo S, et al. Current gaps in HFpEF trials: Time to

reconsider patients' selection and to target phenotypes. *Prog Cardiovasc Dis*.

2021;67:89-97.

34. Sweeney M, Corden B, Cook SA. Targeting cardiac fibrosis in heart failure with

preserved ejection fraction: mirage or miracle? *EMBO Mol Med*. 2020;12(10):e10865.

35. Lewis GA, Dodd S, Clayton D, et al. Pirfenidone in heart failure with preserved ejection

fraction: a randomized phase 2 trial. *Nat Med*. 2021;27(8):1477-1482.

36. Schelbert EB, Fonarow GC, Bonow RO, Butler J, Gheorghiade M. Therapeutic targets in

heart failure: refocusing on the myocardial interstitium. *J Am Coll Cardiol*.

2014;63(21):2188-2198.

37. Schelbert EB, Butler J, Diez J. Why clinicians should care about the cardiac interstitium.

JACC Cardiovasc Imaging. 2019;12(11 Pt 2):2305-2318.

38. Haynes RB, Taylor DW, Sackett DL, Gibson ES, Bernholz CD, Mukherjee J. Can simple

clinical measurements detect patient noncompliance? *Hypertens Dallas Tex 1979*.

1980;2(6):757-764.

Figure 1. Participant Recruitment, Randomization and Treatment

A total of 78 participants were randomized in the trial. One patient in the sacubitril/valsartan

group withdrew at week 4 due to concerns of medication side effects. One patient in the

valsartan group withdrew at week 26 due to difficulties with trial commitment. This

participant had final visit investigations (including cardiovascular magnetic resonance)

performed at time of withdrawal, according to study protocol. Primary and secondary

endpoints were analyzed as intention-to-treat in all 78 participants.

637
Figure 2. Effects of Sacubitril/valsartan Compared to Valsartan on Primary Endpoint

The primary endpoint before and after adjustment for baseline covariates. (A) Unindexed

interstitial volume. (B) Interstitial volume indexed to body surface area. Values are mean

(95% confidence interval).

Figure 3. Blood Pressure Control Between Sacubitril/valsartan and Valsartan

The mean blood pressure assessed at all timepoints during the trial were similar between the

two treatment groups. Vertical bars are mean (95% confidence interval). Values are P value

for between-group comparison.

Figure 4. Central Illustration

Study design and findings of REVERSE-LVH, a randomized phase 2 trial to compare the efficacy between sacubitril/valsartan and valsartan in regressing diffuse interstitial fibrosis in hypertensive patients with left ventricular hypertrophy (LVH). CMR = cardiovascular magnetic resonance; LV = left ventricular; LA = left atrial.

658   **Table 1. Baseline Characteristics of All Randomized Participants**

	All Participants (n=78)	Sacubitril/ valsartan (n=39)	Valsartan (n=39)
Baseline Clinical Characteristics			
Age, y	58±11	56±11	59±11
Males, n (%)	32 (41)	18 (46)	14 (36)
Chinese ethnicity, n (%)	71 (91)	35 (90)	36 (92)
Weight, kg	71±18	74±19	68±16
Body mass index, kg/m^2	27.2±5.6	27.7±6.2	26.7±5.1
Dyslipidemia, n (%)	33 (42)	18 (46)	15 (39)
Diabetes mellitus, n (%)	14 (18)	9 (23)	5 (13)
Smoking, n (%)	6 (8)	3 (8)	3 (8)
24h systolic blood pressure, mmHg	137±14	138±17	137±10
24h diastolic blood pressure, mmHg	81±11	82±11	80±11
Baseline Biochemical Characteristics			
Potassium, mmol/L	3.8 [3.6, 4.0]	3.8 [3.6, 4.0]	3.7 [3.6, 4.0]
Creatinine, µmol/L	72 [52, 86]	73 [51, 88]	72 [54, 85]
NT-proBNP, pg/mL	53 [28, 141]	42 [28, 101]	60 [31, 275]
High sensitivity cTnT, pg/mL	9.8 [6.5, 14.5]	9.5 [6.6, 15.0]	10.9 [6.0, 14.5]
Estimated GFR, mL/min/1.73 m^{2a}	90 [72, 106]	94 [74, 108]	88 [70, 102]
Baseline Cardiovascular Magnetic Resonance Characteristics			
Indexed LV mass, g/m^2	64±19	64±19	64±18
Indexed LV end diastolic volume, mL/m^2	78±15	76±16	79±15
Indexed LV end systolic volume, mL/m^2	32±12	32±13	32±11
Indexed LV stroke volume, mL/m^2	46±7	45±8	47±7
LV ejection fraction	60±9	59±10	60±7
Indexed RV end diastolic volume, mL/m^2	74±13	73±13	74±13
Indexed RV end systolic volume, mL/m^2	28±10	28±9	27±11
Indexed RV stroke volume, mL/m^2	46±7	45±8	47±7
RV ejection fraction	63±9	62±8	64±9
Indexed left atrial volume, mL/m^2	55±15	53±12	56±18
Indexed right atrial area, cm^2/m^2	12.0±2.1	11.7±1.8	12.4±2.2
Remodeling Index	5.33±0.99	5.22±0.80	5.44±1.15
Ventricular-arterial coupling ratio	0.71±0.29	0.74±0.36	0.69±0.22
Estimated LV filling pressure, mmHg	15.6±2.8	15.7±3.0	15.5±2.6
Maximal wall thickness, mm	10.0±2.4	10.1±2.1	9.9±2.7
Mean wall thickness, mm	7.5±1.6	7.7±1.6	7.4±1.6
LV mass/end-diastolic volume ratio	0.83±0.17	0.84±0.14	0.81±0.19

Global longitudinal strain, %	-16.5±3.3	-16.0±3.3	-17.0±3.2
Global circumferential strain, %	-18.7±3.2	-18.2±3.5	-19.1±2.8
Global radial strain, %	32.4±8.6	31.2±9.2	33.6±7.8
Extracellular volume fraction, %	26.4±2.6	26.1±2.4	26.8±2.8
Indexed myocyte volume, mL/m^2	45.0±13.1	45.4±13.7	44.5±12.6
Non ischemic late gadolinium enhancement, n (%)	29 (37)	15 (38)	14 (36)

Values are mean±SD or median [interquartile range] unless otherwise indicated. [a]Estimated

GFR calculated using MDRD equation = 175 x [serum creatinine (µmol/L)/88.4]$^{-1.154}$ × (age)

$^{-0.203}$ × (0.742 if female). Left ventricular hypertrophy was defined based on age- and sex-

specific reference ranges established in the local population (females: 47g/m^2 and males:

65g/m^2). Abnormal global longitudinal strain in the population was defined as < -14.0 to -

15.0% in males and < -17.0 to -18.0% in females[20].

GFR = glomerular filtration rate; LV = left ventricular; RV = right ventricular; NT-proBNP =

N-terminal pro-B-type natriuretic peptide; cTnT = cardiac troponin T

 Table 2. Secondary Endpoints After 52 Weeks of Treatment

	At End of 52 Weeks of Treatment		Change from Baseline to Post-treatment		Treatment Difference	
	Sacubitril/valsartan	Valsartan	Sacubitril/valsartan	Valsartan	95% Confidence Interval	P Value
Indexed LV mass, g/m^2	53±14	58±20	-11.2±10.3	-6.3±5.2	**-8.6 to -1.2**	**0.010**
Indexed LV end diastolic volume, mL/m^2	70±12	75±17	-6.4±8.8	-4.1±8.6	-6.2 to 1.6	0.247
Indexed LV end systolic volume, mL/m^2	28±8	29±15	-4.1±8.9	-3.1±8.0	-4.8 to 2.9	0.622
Indexed LV stroke volume, mL/m^2	42±7	46±7	-2.4±5.0	-1.1±5.6	-3.7 to 1.0	0.263
LV ejection fraction	61±7	62±8	1.2±6.5	2.1±6.2	-3.8 to 1.9	0.511
Indexed RV end diastolic volume, mL/m^2	69±12	72±12	-3.8±6.0	-2.7±9.6	-4.8 to 2.4	0.520
Indexed RV end systolic volume, mL/m^2	27±8	26±9	-1.2±5.6	-1.4±7.7	-2.9 to 3.2	0.925
Indexed RV stroke volume, mL/m^2	42±7	46±8	-2.6±4.7	-1.3±7.3	-4.1 to 1.5	0.349
RV ejection fraction	62±8	64±10	-0.3±6.3	0.1±8.3	-3.7 to 2.9	0.811
Indexed left atrial volume, mL/m^2	43±11	51±17	-9.8±8.7	-5.0±8.0	**-8.5 to -1.0**	**0.013**
Indexed right atrial area, cm^2/m^2	10.8±1.8	11.7±2.0	-0.8±1.4	-0.7±1.3	-0.7 to 0.5	0.772
LV mass/end-diastolic volume ratio	0.76±0.14	0.77±0.20	-0.08±0.09	-0.04±0.09	-0.08 to 0.00	0.072
Remodeling Index	5.69±0.89	5.82±1.34	0.46±0.56	0.38±0.50	-0.17 to 0.31	0.544
Ventricular-arterial coupling ratio	0.67±0.21	0.64±0.34	-0.07±0.26	-0.04±0.23	-0.14 to 0.09	0.655
Estimated LV filling pressure, mmHg	13.8±2.3	14.6±2.7	-1.8±1.5	-0.9±1.1	**-1.5 to -0.3**	**0.003**
Maximal wall thickness, mm	9.0 ± 1.7	9.1±2.7	-1.1±1.0	-0.7±0.7	-0.8 to 0.0	0.065

Global longitudinal strain, %	-17.0±2.5	-16.8±3.3	-0.9±2.3[a]	0.2±1.9	**-2.0 to -0.1**	**0.027**
Global circumferential strain, %	-18.9±2.6	-19.1±2.8	-0.6±2.2[a]	-0.03±1.9[a]	-1.5 to 0.4	0.253
Global radial strain, %	33.1±7.6	33.4±7.1	1.7±6.5	-0.2±5.8	-0.9 to 4.7	0.189
Extracellular volume fraction, %	26.4±2.6	27.1±2.8	0.3±2.0	0.3±2.7	-1.1 to 1.1	0.962
Indexed myocyte volume, mL/m^2	37.2±9.7	39.9±13.4	-8.4±7.9	-4.6±4.2	**-2.3 to -0.4**	**0.010**

670   [a]Negative value signifies an improvement in strain.

671   LV = left ventricular; RV = right ventricular.

672   Values are mean±SD

673 **Table 3. Renal Function Between Treatment Groups Throughout Study Trial**

	Week	Sacubitril/ valsartan	Valsartan	P value
Potassium, mmol/L	0	3.8 [3.6, 4.0]	3.7 [3.6, 4.0]	0.800
	4	3.9 [3.7, 4.3]	4.0 [3.7, 4.3]	0.778
	8	4.0 [3.8, 4.2]	4.0 [3.9, 4.2]	0.766
	26	4.1 [3.7, 4.5]	4.1 [3.9, 4.3]	0.765
	52	3.9 [3.6, 4.2]	3.8 [3.5, 4.2]	0.602
Estimated GFR, mL/min/1.73m^2	0	94 [74, 108]	88 [70, 102]	0.420
	4	82 [68, 108]	84 [74, 100]	0.996
	8	86 [71, 102]	82 [63, 110]	0.909
	26	89 [65, 107]	84 [70, 97]	0.897
	52	89 [63, 104]	83 [69, 100]	0.796

675 Values are median [inter-quartile range]. Values between treatment groups were compared

676 with Mann-Whitney U test. GFR = glomerular filtration rate.